# NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals

Study · id `cardio:ct-nct04055428` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04055428](<https://clinicaltrials.gov/study/NCT04055428>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04055428

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04055428. Randomized; quadruple masking; primary purpose treatment. Start 2020-08-15 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04055428, source copy `cardio:ctgov-nct04055428-2026-07-28`, retrieved 2026-10-26)
- Started: 2020-08-15 (actual) (ClinicalTrials.gov record NCT04055428, source copy `cardio:ctgov-nct04055428-2026-07-28`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT04055428, source copy `cardio:ctgov-nct04055428-2026-07-28`, retrieved 2026-10-26)
- Completion: 2027-05-31 (anticipated) (ClinicalTrials.gov record NCT04055428, source copy `cardio:ctgov-nct04055428-2026-07-28`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04055428, source copy `cardio:ctgov-nct04055428-2026-07-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04055428-2026-07-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
- Condition: Diabetes Mellitus
- Condition: Cardiovascular Diseases
- Condition: Insulin Sensitivity/Resistance
- Condition: Metabolic Disease
- Condition: Natriuretic Peptides
- Condition: Metabolism
- Condition: Energy Expenditure
- Intervention (Drug): Sacubitril, Valsartan 97-103 mg Oral Tablet
- Intervention (Drug): Valsartan 160 mg
- Intervention (Other): Intravenous Glucose Tolerance Test
- Intervention (Dietary supplement): Standardized Meals
- Intervention (Other): Exercise capacity VO2 maximum determination
- Lead sponsor: University of Alabama at Birmingham
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: University of Alabama at Birmingham (`cardio:org-university-of-alabama-at-birmingham`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: ecf4687421f105b9db0ecf78fa5e9627891f30c3b7f1ea9eaa158f00aacea928
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
